AIM
BIIB icon

Artemis Investment Management’s Biogen BIIB Stock Holding History

Artemis Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$131M Buy
581,774
+10,800
+2% +$2.29M 1.15% 26
2026
Q2 		$123M Sell
570,974
-597
-0.1% -$114K 1.1% 24
2026
Q1 		$105M Buy
571,571
+344,726
+152% +$63.5M 1.11% 25
2025
Q4 		$39.9M Buy
+226,845
New +$37.1M 0.48% 77
2022
Q4 		– Sell
-21,074
Closed -$5.63M – 226
2022
Q3 		$5.63M Buy
+21,074
New +$4.48M 0.06% 172
2020
Q3 		– Sell
-21,186
Closed -$5.68M – 251
2020
Q2 		$5.68M Sell
21,186
-23,086
-52% -$6.94M 0.08% 207
2020
Q1 		$14M Sell
44,272
-5,861
-12% -$1.78M 0.02% 101
2019
Q4 		$14.9M Sell
50,133
-33,363
-40% -$9.26M 0.19% 130
2019
Q3 		$19.4M Buy
83,496
+3,835
+5% +$893K 0.27% 111
2019
Q2 		$18.6M Buy
79,661
+17,901
+29% +$4.13M 0.22% 134
2019
Q1 		$14.6M Buy
61,760
+24,461
+66% +$7.7M 0.17% 159
2018
Q4 		$11.2M Sell
37,299
-11,668
-24% -$3.72M 0.15% 165
2018
Q3 		$17.3M Buy
48,967
+29,244
+148% +$10.1M 0.19% 137
2018
Q2 		$5.72M Buy
19,723
+398
+2% +$112K 0.08% 192
2018
Q1 		$5.29M Sell
19,325
-5,522
-22% -$1.71M 0.08% 178
2017
Q4 		$7.92M Sell
24,847
-49,143
-66% -$15.8M 0.13% 149
2017
Q3 		$23.2M Buy
73,990
+59,651
+416% +$17.7M 0.48% 57
2017
Q2 		$3.89M Buy
14,339
+1,340
+10% +$354K 0.09% 170
2017
Q1 		$3.56M Sell
12,999
-28,000
-68% -$7.92M 0.1% 152
2016
Q4 		$11.6M Buy
40,999
+20,995
+105% +$6.22M 0.31% 83
2016
Q3 		$6.26M Sell
20,004
-35,162
-64% -$10.4M 0.18% 130
2016
Q2 		$13.3M Buy
55,166
+37,015
+204% +$9.76M 0.36% 77
2016
Q1 		$4.73M Sell
18,151
-8,156
-31% -$2.15M 0.12% 141
2015
Q4 		$8.06M Buy
+26,307
New +$7.56M 0.2% 114
2015
Q2 		– Sell
-18,388
Closed -$7.77M – 231
2015
Q1 		$7.77M Sell
18,388
-112
-0.6% -$44.1K 0.31% 82
2014
Q4 		$6.29M Sell
18,500
-300
-2% -$97.1K 0.24% 101
2014
Q3 		$6.22M Buy
+18,800
New +$6.2M 0.31% 92

Other funds holding BIIB

BVL
Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Artemis Investment Management's BIIB Position: Q3 2026 in Review

Artemis Investment Management increased its Biogen (BIIB) stake by 1.9% in Q3 2026, buying an estimated $2.29M and bringing the position to 581,774 shares worth $131M. The position accounts for 1.15% of the portfolio, ranked #26.

Artemis Investment Management first reported a position in BIIB in Q3 2014 and has held it in 27 quarters since. 76 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Artemis Investment Management held 581,774 shares of Biogen worth $131M as of Q3 2026.
  • Artemis Investment Management bought 10,800 Biogen shares in Q3 2026, an estimated $2.29M.
  • Biogen made up 1.15% of Artemis Investment Management's portfolio in Q3 2026, its #26 holding.
  • Artemis Investment Management first reported a position in Biogen in Q3 2014 and has held it in 27 quarters since.
  • 76 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Artemis Investment Management's 13F filing for Q3 2026, filed 8 Oct 2026.